PALVELLA THERAPEUTICS, INC. Segments Disclosure
Note 14. Segment Information
The Company is comprised of one reportable segment, the Company operations. As of December 31, 2024, the Company operations segment has not generated any product revenue since inception, as it does not yet have approved products for sale. However, the Company operations segment anticipates future revenue generation upon the successful development and commercialization of product candidates either independently or through partnerships.
The Company expects to primarily generate revenue in North America, with its long-lived assets also concentrated in this region, and manages its business activities on a consolidated basis. Decisions concerning the allocation of the Company’s resources are made by the Company’s Chief Operating Decision Maker (CODM), which is the Company’s (CEO). The CODM views the Company’s operations as a operating segment which is the business of discovering and developing products for individuals with serious and rare genetic skin diseases.
The Company’s significant segment expenses that are regularly provided to the CODM are related to:
The CODM assesses performance for the Company operations segment and decides how to allocate resources based on net income or loss that is also reported on the income statement as consolidated net income or loss and the measure of segment assets as reported on the balance sheet as total consolidated assets. Net income or loss is used to monitor budget versus actual results as well as assess the general performance of the segment in a given period.
The following table reconciles segment direct profit or loss to the Company’s consolidated results:
|
Year Ended December 31, |
|
|||||
(in thousands) |
2024 |
|
|
2023 |
|
||
Research and development: |
|
|
|
|
|
||
QTORIN rapamycin for PC and GS |
$ |
— |
|
|
$ |
3,682 |
|
QTORIN rapamycin for microcystic LM |
|
1,929 |
|
|
|
164 |
|
QTORIN rapamycin for microcystic LM - Government grant income |
|
(141 |
) |
|
|
— |
|
QTORIN rapamycin for cutaneous VM |
|
296 |
|
|
|
— |
|
QTORIN rapamycin CMC |
|
1,601 |
|
|
|
878 |
|
Non-program specific and unallocated research and development expenses: |
|
|
|
|
|
||
Salaries and stock-based compensation |
|
2,810 |
|
|
|
2,383 |
|
Consultants |
|
1,040 |
|
|
|
1,229 |
|
Other |
|
616 |
|
|
|
457 |
|
Total research and development |
$ |
8,151 |
|
|
$ |
8,793 |
|
General and administrative: |
|
|
|
|
|
||
Salaries and stock-based compensation |
$ |
1,935 |
|
|
$ |
821 |
|
Consultants |
|
2,961 |
|
|
|
605 |
|
Other |
|
1,048 |
|
|
|
1,650 |
|
Total general and administrative |
$ |
5,944 |
|
|
$ |
3,076 |
|
Loss from operations |
$ |
(14,095 |
) |
|
$ |
(11,869 |
) |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.